Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference

This article was originally published in The Pink Sheet Daily

Executive Summary

China’s State FDA plans to launch a drug master file system and may integrate that system into existing regulations.

You may also be interested in...

China’s State FDA To Implement Electronic Tracking Network To Improve Drug Safety

SHANGHAI - China's State SFDA will implement an electronic ID-based drug-tracking system this year, the drug watchdog announced at a monthly press conference April 8

China State FDA Issues Warning In Wake Of Heparin Safety Concerns

SHANGHAI - In the wake of a U.S. safety scare related to Baxter Healthcare's heparin, China's State FDA has warned foreign pharmaceutical companies to conduct business with only licensed Chinese companies

Chinese Heparin API Manufacturer Not Inspected By SFDA

SHANGHAI - China's State FDA has never inspected an API manufacturer that may be linked to a safety scare over Baxter Healthcare's injectable heparin, officials confirmed to PharmAsia News


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts